Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Jul 9, 2026
•
4 min read
Ipsen lands Phase III migraine data, Tarsus adds IRX-101, and FDA pauses new CRL disclosures.
Jul 8, 2026
Vera flips to launch mode in IgA nephropathy, Kailera's oral GLP-1 clears Phase 3, and AZ crashes Merck's COPD party.
Jul 7, 2026
Vertex's biggest-ever check, Genmab's bispecific clears Europe, and CMS takes an axe to 340B.
Jul 6, 2026
Plus AZ's fourth CSPC raid, United's $300M thymus bet, and a soft-jobs tape.
Jul 2, 2026
Roche posts a phase III KRAS win, Orca clears the FDA, and Novartis lands an EU SMA nod.
Jul 1, 2026
Ipsen buys Memo, Canada clears generic Wegovy, and Boulevard rents a $1.6B China T-cell engager.
Jun 30, 2026
Sanofi clears a Pompe hurdle, Roche grabs a TED PDUFA, and Nuvectis grabs $100M while the window's open.
Jun 29, 2026
Ipsen buys Kartos, Viridian gets its TED approval, and Tavneos faces a sharper regulatory overhang.
Jun 26, 2026
Biogen takes the red pen to Apellis; Ionis hands off zilganersen
